Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Novartis
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A randomized, multicenter, double-blind, 6 week study to evaluate the dose response of valsartan on blood pressure reduction in children 1-5 years old with hypertension, followed by a 2 week placebo withdrawal period
To evaluate a dose dependent reduction in MSSBP when comparing three doses of valsartan (0.25 mg,/kg, 1 mg/kg and 4 mg/kg ) over a 6 week period in children 1-5 years old with hypertension ( ≥ 95th p...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Vaccines and Diagnostics GmbH & Co. KG
Update Il y a 4 ans
A phase IV, open-label, single-center study in adolescents and adults: Evaluation of immunogenicity and safety of the first booster immunization with Chiron’s TBE vaccine for adults in participants of study V48P7 and long-term evaluation of immunogenicity up to 5 years after first booster immunization
Descriptive evaluation of subjects with respect to antibody titers and percentage of subjects with neutralizing antibodies on Day 0 (i.e., day of first booster immunization after primary immunization ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma GmbH
Update Il y a 4 ans
A randomized, open-label, multicentric parallel group study to assess the impact of supportive measures on the drug adherence of patients with essential hypertension treated with Valsartan or Valsartan plus HCTZ for 34 weeks with or without respective measures
To demonstrate that supportive measures improve drug adherence in patients with mild essential hypertension treated with valsartan 160 mg or valsartan 160 mg plus HCTZ 12.5 mg for 34 weeks. To assess ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Novartis Pharma
Update Il y a 4 ans
CLEE011X2101 : Essai de phase 1, en escalade de doses, évaluant la tolérance du LEE011, un inhibiteur de CDK4/6, chez des patients ayant une tumeur solide avancée ou un lymphome. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est de déterminer la dose de LEE011 à administrer, chez des patients ayant une tumeur solide avancée ou un lymphome. Les patients recevront des comprimés de LEE011, une fois p...
Country
France
organs
Tumeurs solides
,
Lymphomes non hodgkinien
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Novartis Farmaceútica S.A
Update Il y a 4 ans
Extension E-03 al Protocolo nº RAD001AB253 Estudio de seguimiento de 2 años para obtener datos especificos de la evolución de los pacientes de novo trasplantados cardíacos que discontinuaron la medicación de estudio de forma precoz en el estudio RAD001AB253 Extension E-03 to Protocol No. RAD001A B253 Tiene también en cuenta la Enmienda nº1 al Protocolo RAD001B253E3
Se trata de una extensión de seguimiento de un estudio multicéntrico, aleatorizado, doble ciego, con doble enmascaramiento, con control activo, de 2 años de duración, de eficacia y de seguridad, para ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Novartis Pharma GmbH
Update Il y a 4 ans
Study to investigate the combination of Afinitor with paclitaxel and carboplatin in advanced large cell lung cancer
The primary objective of this study is to evaluate the efficacy of RAD001 in patients with advanced (stage IV) Lung Cancer (Large Cell) with neuroendocrine differentiation treated with a combination o...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A 34-week extension to a 28-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study to assess AIN457 versus placebo in inducing and maintaining uveitis suppression in adults with active, noninfectious, intermediate, posterior, or panuveitis requiring immunosuppression (INSURE Study)
To evaluate the efficacy of continuous treatment with subcutaneous AIN457 compared to placebo for maintaining quiescence of intraocular inflammation and the prevention of active intermediate, posterio...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Farma SpA
Update Il y a 4 ans
Long-term follow-up at 10-years of patients enrolled in the fingolimod Phase II program in relapsing multiple sclerosis
To investigate whether continuous use of fingolimod over 10 years reduces the progression of disability, as measured by the mean Expanded Disability Status Scale (EDSS) score, compared to shorter trea...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman
Between 18 years
and 99 years
Novartis Pharma
Update Il y a 6 ans
Étude CLEE011X2107 : étude de phase 1-2, en escalade de dose, évaluant la tolérance et l’efficacité d’un traitement association le LEE011, un inhibituer de CDK4/6 et le BYL719, un inhibiteur de PI3K, avec de létrozole, chez des patientes ayant un cancer du sein avancé ER+. [Informations issues du site clinicaltrials.gov et traduites par l'INCa]
CLEE011X2107 : A Phase Ib/II, Multicenter Study of the Combination of LEE011 and BYL719 With Letrozole in Adult Patients With Advanced ER+ Breast Cancer
Country
France
organs
Sein
Specialty
Thérapies Ciblées
,
Hormonothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Novartis Farma S.p.A
Update Il y a 4 ans
Study to evaluate the renal function of adult liver transplant recipients treated with two everolimus-based immunosuppressive regimens (tacrolimus withdrawal vs. minimization) until 12 months post-transplant, with a 6-months follow-up
To compare at Month 12 post-transplantation the renal function, measured by estimated GFR (MDRD-4), between tacrolimus withdrawal regimen and early tacrolimus minimization regimen, both facilitated by...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
7
8
9
10
11
12
13
14
15
16
Next